BRD4 and prostate carcinoma: SPOP-inactivating mutations in prostate cancer cells stabilize Brd4 and confer resistance to BETi, while SPOP-activating mutations in colorectal cancer cells with reduced Brd4 expression are exquisitely sensitive to BETi and prone to apoptosis [48, 134].